Loading
Aldoxorubicin is doxorubicin, the workhorse chemotherapy nicknamed the red devil, attached to a linker that hitches it to the body's own albumin so more reaches the tumour and less reaches the heart; it beat doxorubicin in a randomised phase 2 sarcoma trial but missed the primary endpoint of its phase 3, and a new company is now trying to finish its development.
Aldoxorubicin was invented by Felix Kratz at the Tumor Biology Center in Freiburg and developed by CytRx. In a randomised phase 2b trial of 140 patients with previously untreated advanced soft tissue sarcoma, it improved progression-free survival over doxorubicin (median 5.6 versus 2.7 months) and allowed cumulative doxorubicin-equivalent doses far above the usual cardiac ceiling. The 433-patient phase 3 trial in relapsed soft tissue sarcoma compared it with investigator's choice of dacarbazine, pazopanib, gemcitabine with docetaxel, doxorubicin or ifosfamide and did not meet its primary progression-free survival endpoint, and CytRx licensed the drug to ImmunityBio in 2017, which has tested it with its IL-15 agonist in pancreatic cancer. Gemini Therapeutics, formed after the GitLab co-founder Sid Sijbrandij was treated with doxorubicin for osteosarcoma, took up the programme and presented integrated analyses at ASCO 2026 reporting higher tumour exposure than doxorubicin and better preserved cardiac function across the randomised sarcoma studies. It is not approved anywhere.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Doxorubicin joined through an acid-sensitive hydrazone linker to a maleimide that bonds covalently to circulating albumin within minutes of injection; albumin carries the drug into tumours, where the acidic microenvironment and lysosomes cleave the linker and release doxorubicin, keeping free doxorubicin in the blood and heart low. Connects to Topoisomerase II alpha (TOP2A).
1.Aldoxorubicin slips into a pocket on Topoisomerase II alpha (TOP2A).
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Aldoxorubicin" OR ABSTRACT:"Aldoxorubicin" OR TITLE:"INNO-206" OR ABSTRACT:"INNO-206" OR TITLE:"DOXO-EMCH" OR ABSTRACT:"DOXO-EMCH" OR TITLE:"Aldox" OR ABSTRACT:"Aldox") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Aldoxorubicin, not a curated reading list.
Shares Doxorubicin and the tag owner-request.
Shares Cytotoxic chemotherapy and the tag owner-request.
Shares Pancreatic ductal adenocarcinoma and the tag owner-request.
Shares Pancreatic ductal adenocarcinoma and the tag owner-request.
Shares Topoisomerase II alpha (TOP2A), Doxorubicin, Cytotoxic chemotherapy.
Shares ImmunityBio, Cytotoxic chemotherapy.
Shares ImmunityBio, Cytotoxic chemotherapy.
Shares Topoisomerase II alpha (TOP2A), Cytotoxic chemotherapy.